MedTrace Logo

National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients

NCT01362933 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 502

Last updated 2015-03-06

No results posted yet for this study

Summary

Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.

Conditions

  • Neoplasms
  • Venous Thromboembolism

Interventions

PROCEDURE

VTE treatment in cancer patient description

proportion of patients treated for evolutive VTE according to international recommendations

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    collaborator OTHER

  • Groupe Francophone Thrombose et Cancer (GFTC)

    collaborator UNKNOWN

  • University Hospital, Grenoble

    collaborator OTHER

  • Floralis

    lead INDUSTRY

Principal Investigators

  • Marie-Antoinette SEVESTRE, MD · Centre Hospitalier Universitaire, Amiens

  • Dominique FARGE BANCEL, MD · GFTC

  • Jean Luc BOSSON, MD · University Hospital, Grenoble

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-01-31
Completion
2012-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01362933 on ClinicalTrials.gov